Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any primary ciliary dyskinesia in which the cause of the disease is a mutation in the DNAI2 gene.
Features include always present findings: Decreased nasal nitric oxide, Chronic sinusitis, Absent outer dynein arms, and Recurrent otitis media and others; and very common findings: Bronchiectasis. 14 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lungs and breathing | 3 | Bronchiectasis, Pneumonia, Neonatal respiratory distress |
DNAI2 encodes dynein axonemal intermediate chain 2 (605 aa). Component of dynein, a family of motor proteins essential for movement along microtubules. Required for structural and functional integrity of cilia. Part of the dynein complex of respiratory cilia Highest expression in Testis (57.9 TPM) and Fallopian Tube (5.7 TPM).
Primary ciliary dyskinesia 9 is caused by mutations in the DNAI2 gene on chromosome 17.
DNAI2 is classified as a druggable target (External Side Of Plasma Membrane category) with score 0.0.
Genetic testing for DNAI2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for primary ciliary dyskinesia 9 has been reported in the published literature.
Phenotype severity distribution: 5 always present features, 1 very common feature, 2 common features.
No clinical trials have been registered for primary ciliary dyskinesia 9.
165 publications have been identified in PubMed for primary ciliary dyskinesia 9. Research spans Epidemiology / Natural History (25%), Review / Meta-Analysis (20%), and Case Report / Case Series (19%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 39 | 25% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 11:54 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Ears |
2 |
Recurrent otitis media, Chronic otitis media |
Hormones | 1 | Male infertility |
Brain and nerves | 1 | Ciliary dyskinesia |
Pregnancy and birth | 1 | Neonatal respiratory distress |
Age of onset: newborn period.
Research summaries
31 |
20% |
Patient case studies | 30 | 19% |
Laboratory research | 23 | 15% |
Testing and diagnosis research | 17 | 11% |
Clinical study results | 12 | 8% |
New treatment approaches | 5 | 3% |
Other research | 1 | 1% |
Erdem Eralp E (2026). [PMID: 41103006](https://pubmed.ncbi.nlm.nih.gov/41103006/). *Expert Rev Respir Med*. [Review / Meta-Analysis]
Wada R (2026). [PMID: 41621888](https://pubmed.ncbi.nlm.nih.gov/41621888/). *Intern Med*. [Epidemiology / Natural History]
Wang S (2026). [PMID: 42317261](https://pubmed.ncbi.nlm.nih.gov/42317261/). *Front Genet*. [Case Report / Case Series]
Feng XQ (2026). [PMID: 42304999](https://pubmed.ncbi.nlm.nih.gov/42304999/). *Zhongguo Dang Dai Er Ke Za Zhi*. [Case Report / Case Series]
Lei W (2026). [PMID: 41807802](https://pubmed.ncbi.nlm.nih.gov/41807802/). *Reprod Sci*. [Basic Science / Preclinical]
Wucherpfennig L (2026). [PMID: 41741347](https://pubmed.ncbi.nlm.nih.gov/41741347/). *Ann Am Thorac Soc*. [Diagnostic / Biomarker]
Yang B (2026). [PMID: 41758249](https://pubmed.ncbi.nlm.nih.gov/41758249/). *Biol Open*. [Basic Science / Preclinical]
Nayir Buyuksahin H (2026). [PMID: 41999583](https://pubmed.ncbi.nlm.nih.gov/41999583/). *Pediatr Pulmonol*. [Basic Science / Preclinical]
Monroy-Jiménez MA (2026). [PMID: 41586127](https://pubmed.ncbi.nlm.nih.gov/41586127/). *Eur Heart J Case Rep*. [Case Report / Case Series]
Ong JWY (2026). [PMID: 42386308](https://pubmed.ncbi.nlm.nih.gov/42386308/). *Eur Respir Rev*. [Review / Meta-Analysis]